Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates

Pediatrics

Volumn 108, Issue 2 II, 2001, Pages 468-471

  El Hassan, N O ^a   Chess, P R ^a   Huysman, M W A ^a   Merkus, P J F M ^a   De Jongste, J C ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Atelectasis; Bronchopulmonary dysplasia; Dornase alfa; Infection; rhDNase

Indexed keywords

DORNASE ALFA; SURFACTANT;

ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; BRONCHUS MUCUS; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG DYSPLASIA; LUNG INFECTION; MALE; NEBULIZATION; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME;

ADMINISTRATION, INHALATION; AIRWAY OBSTRUCTION; ATELECTASIS; DEOXYRIBONUCLEASE I; EXPECTORANTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MALE; MUCUS; RADIOGRAPHY, THORACIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0034884994     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.108.2.468     Document Type: Article

References (16)

1. Clinical pharmacology of mucokinetics drugs
2. Mucus-controlling agents
3. Studies on pulmonary secretions: The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy
4. Recombinant human DNase reduces the viscosity of cystic fibrosis sputum
5. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis
6. Human recombinant DNase for mucus plugging in status asthmaticus
7. Resolution of chronic atelectasis in a child with asthma after aerosolized recombinant human DNase
8. Recombinant human DNase in management of lobar atelectasis due to retained secretions
9. Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase
10. DNase treatment in primary ciliary dyskinesia - Assessment by nocturnal pulse oximetry
11. Resolution of mucusplugging and atelectasis after intracheal RhDNase therapy in a mechanically ventilated child with refractory status asthmaticus
12. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum
13. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis
14. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: Many promises, more problems
15. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
16. Safety of endotracheal rhDNase for treatment of pulmonary atelectasis in mechanically ventilated children